Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II

Duhoux, François;Jager, Agnes;Dirix, Luc;Huizing, Manon;Triebel, Frederic;et.al.
(2017) Annual Meeting of the American Society of Clinical Oncology (ASCO) — Location: Chicago, IL, USA (4.June.2017)

Files

No attached file found for this publication.

Details

Authors
  • Duhoux, Françoisorcid-logoUCLouvain
    Author
  • Jager, AgnesErasmus MC Cancer Institute, Rotterdam, Netherlands
    Author
  • Dirix, LucOncology Center GZA Hospitals Sint Augustinus, Translational Cancer Research Unit, Department of Medical Oncology, Antwerp, Belgium
    Author
  • Huizing, ManonAntwerp University Hospital, Edegem, Belgium
    Author
  • Vuylsteke, PeterUCLouvain
    Author
  • Mueller, ChristianUCLouvain
    Author
  • Triebel, FredericUCLouvain
    Author
Show more
Affiliations

Citations

  • APA
  • Chicago
  • FWB

Duhoux, F., Jager, A., Dirix, L., Huizing, M., Jerusalem, G., Vuylsteke, P., De Cuypere, E., Breiner, D., Mueller, C., Brignone, C., & Triebel, F. (2017). Combination of paclitaxel and LAG3-Ig (IMP321), a novel MHC class II agonist, as a first-line chemoimmunotherapy in patients with metastatic breast carcinoma (MBC): interim results from the run-in phase of a placebo controlled randomized phase II. Journal of Clinical Oncology, 35(suppl), abstr 1062. https://hdl.handle.net/2078.5/90076 (Original work published 2017)